Skip to content

Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences

Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01477372
Enrollment
320
Registered
2011-11-22
Start date
2007-09-30
Completion date
2011-02-28
Last updated
2012-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

Pregnancy, Exercise, Excessive weight gain, Outcomes, Urinary incontinence

Brief summary

The purpose of this study was to assess the effectiveness of a moderated physical exercise program called Blooming Exercise Program (BEP) developed during pregnancy in order to control excessive maternal weight gain and its consequences. Additionally, other objectives of the study were to analyse the influence of BEP on urinary incontinence, on the other pregnancy outcomes and on the perception of the pregnant's health

Detailed description

BACKROUND: Pregnancy and delivery can condition significantly women's health. In particular, an excessive gain of weight during pregnancy constitutes a risk factor which may lead to (i) different alterations during pregnancy such as gestational diabetes or hypertension, (ii) foetus health problems (macrosomia), (iii) delivery complications (dystocia, prolonged labour and increased number of caesareans) and (iv) future health disorders for the woman (overweight, obesity and cardiovascular alterations). Furthermore, during pregnancy pelvic floor health problems, such as urinary incontinence (IU) may arise or worsen. OBJECTIVES: The main aim of this study was to assess the effectiveness of a moderate physical exercise program called Blooming Exercise Program (BEP) developed during pregnancy in order to control excessive maternal weight gain and its consequences. Additionally, other objectives of the study were to analyse the influence of BEP on urinary incontinence, on the other pregnancy outcomes (maternal and foetal) and on the perception of the pregnant's health. DESIGN: A randomized, controlled trial called has been conducted. 300 healthy pregnant women were recruited and divided into an intervention group (IG, n=100) and a control group (CG, n=200). The IG participated in BEP as from week 10-12 of gestation (at least 56 sessions through 22 weeks. 3 sessions per week). The CG did not participate in any supervised program addressed to pregnant women but received regular health care. Pregnancy outcomes regarding the mother and the new born, urinary incontinence and women's habits data were obtained and registered through initial interviews, medical records and two specific questionnaires on health and urinary incontinency (ICIQ-SF and King's).

Interventions

Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week

Sponsors

Universidad Politecnica de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy pregnant women * Delivering in Hospital Universitario de Fuenlabrada * At week 10-14 of gestation * Able to attend 3 sessions per week until the end of the pregnancy

Exclusion criteria

* Contraindications appointed by ACOG * Less than 56 sessions

Design outcomes

Primary

MeasureTime frameDescription
Maternal weight gainweek 36-38 of gestationMaternal weight gain and proportion of participants exceeding weight gain above IOM (2009) recommendations

Secondary

MeasureTime frame
Excessive weight gain related risks (gestational diabetes, macrosomia, type of delivery)week 36-38 of gestation
Urinary incontinenceweek 36-38 of gestation
Other pregnancy outcomes (maternal and foetal)week 36-38 of gestation

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026